Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The mammalian target of rapamycin (mTOR) was recently identified in two structurally distinct multiprotein complexes: mTORC1 and mTORC2. Previously, we found that Rictor/mTORC2 protects against cisplatin-induced acute kidney injury, but the role and mechanisms for Rictor/mTORC2 in TGFβ1-induced fibroblast activation and kidney fibrosis remains unknown. To study this, we initially treated NRK-49F cells with TGFβ1 and found that TGFβ1 could activate Rictor/mTORC2 signaling in cultured cells. Blocking Rictor/mTORC2 signaling with Rictor or Akt1 small interfering RNAs markedly inhibited TGFβ1-induced fibronection and α-smooth muscle actin expression. Ensuing western blotting or immunostaining results showed that Rictor/mTORC2 signaling was activated in kidney interstitial myofibroblasts from mice with unilateral ureteral obstruction. Next, a mouse model with fibroblast-specific deletion of Rictor was generated. These knockout mice were normal at birth and had no obvious kidney dysfunction or kidney morphological abnormality within 2 months of birth. Compared with control littermates, the kidneys of Rictor knockout mice developed less interstitial extracellular matrix deposition and inflammatory cell infiltration at 1 or 2 weeks after ureteral obstruction. Thus our study suggests that Rictor/mTORC2 signaling activation mediates TGFβ1-induced fibroblast activation and contributes to the development of kidney fibrosis. This may provide a therapeutic target for chronic kidney diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury
Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V., & Bonventre, J. V. (2010) · Nature Medicine · doi:10.1038/nm.2144 · Cited by 1,333
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress
Grahammer, F., Haenisch, N., Steinhardt, F., Sandner, L., Roerden, M., Arnold, F., Cordts, T., Wanner, N., Reichardt, W., Kerjaschki, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402352111 · Cited by 109
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
Caja, L., Dituri, F., Mancarella, S., Caballero-Diaz, D., Moustakas, A., Giannelli, G., & Fabregat, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051294 · Cited by 351
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
Wnt/β-Catenin–Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis
Feng, Y., Ren, J., Gui, Y., Wei, W., Shu, B., Lu, Q., Xue, X., Sun, X., He, W., Yang, J., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040391 · Cited by 271
Self-citationPartial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis
Lovisa, S., Zeisberg, M., & Kalluri, R. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.06.004 · Cited by 255
Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis
Ding, H., Jiang, L., Xu, J., Bai, F., Zhou, Y., Yuan, Q., Luo, J., Zen, K., & Yang, J. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00036.2017 · Cited by 250
Self-citationRoles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Protein kinase Cα drives fibroblast activation and kidney fibrosis by stimulating autophagic flux
Xue, X., Ren, J., Sun, X., Gui, Y., Feng, Y., Shu, B., Wei, W., Lu, Q., Liang, Y., He, W., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002191 · Cited by 40
Self-citation
Metadata
- Authors
- Li, J., Ren, J., Liu, X., Jiang, L., He, W., Yuan, W., Yang, J., & Dai, C.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 88
- Issue
- 3
- Pages
- 515-527
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2257962987
- Cited by
- 93
- References
- 6
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.